NCT02556606View on ClinicalTrials.gov

Ketamine for Treatment Resistant Late-Life Depression

PHASE3CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

October 1, 2015

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2020

Conditions
Treatment Resistant Depressive Disorder
Interventions
DRUG

Ketamine

randomly assigned to a single 40 min infusion of either KET 0.1mg/Kg

DRUG

Ketamine

randomly assigned to a single 40 min infusion of either KET 0.25mg/Kg

DRUG

Ketamine

randomly assigned to a single 40 min infusion of either KET 0.50mg/Kg

DRUG

Midazolam

single 40 min infusion of MID 0.03mg/Kg

Trial Locations (1)

77030

Michael E. DeBakey VA Medical Center, Houston, TX, Houston

All Listed Sponsors
lead

VA Office of Research and Development

FED

NCT02556606 - Ketamine for Treatment Resistant Late-Life Depression | Biotech Hunter | Biotech Hunter